Skip to main content
Top
Published in: Gastric Cancer 5/2023

Open Access 03-06-2023 | Gastric Cancer | Original Article

Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study

Authors: Gregory Patrick Veldhuizen, Christoph Röcken, Hans-Michael Behrens, Didem Cifci, Hannah Sophie Muti, Takaki Yoshikawa, Tomio Arai, Takashi Oshima, Patrick Tan, Matthias P. Ebert, Alexander T. Pearson, Julien Calderaro, Heike I. Grabsch, Jakob Nikolas Kather

Published in: Gastric Cancer | Issue 5/2023

Login to get access

Abstract

Introduction

The Laurén classification is widely used for Gastric Cancer (GC) histology subtyping. However, this classification is prone to interobserver variability and its prognostic value remains controversial. Deep Learning (DL)-based assessment of hematoxylin and eosin (H&E) stained slides is a potentially useful tool to provide an additional layer of clinically relevant information, but has not been systematically assessed in GC.

Objective

We aimed to train, test and externally validate a deep learning-based classifier for GC histology subtyping using routine H&E stained tissue sections from gastric adenocarcinomas and to assess its potential prognostic utility.

Methods

We trained a binary classifier on intestinal and diffuse type GC whole slide images for a subset of the TCGA cohort (N = 166) using attention-based multiple instance learning. The ground truth of 166 GC was obtained by two expert pathologists. We deployed the model on two external GC patient cohorts, one from Europe (N = 322) and one from Japan (N = 243). We assessed classification performance using the Area Under the Receiver Operating Characteristic Curve (AUROC) and prognostic value (overall, cancer specific and disease free survival) of the DL-based classifier with uni- and multivariate Cox proportional hazard models and Kaplan–Meier curves with log-rank test statistics.

Results

Internal validation using the TCGA GC cohort using five-fold cross-validation achieved a mean AUROC of 0.93 ± 0.07. External validation showed that the DL-based classifier can better stratify GC patients' 5-year survival compared to pathologist-based Laurén classification for all survival endpoints, despite frequently divergent model-pathologist classifications. Univariate overall survival Hazard Ratios (HRs) of pathologist-based Laurén classification (diffuse type versus intestinal type) were 1.14 (95% Confidence Interval (CI) 0.66–1.44, p-value = 0.51) and 1.23 (95% CI 0.96–1.43, p-value = 0.09) in the Japanese and European cohorts, respectively. DL-based histology classification resulted in HR of 1.46 (95% CI 1.18–1.65, p-value < 0.005) and 1.41 (95% CI 1.20–1.57, p-value < 0.005), in the Japanese and European cohorts, respectively. In diffuse type GC (as defined by the pathologist), classifying patients using the DL diffuse and intestinal classifications provided a superior survival stratification, and demonstrated statistically significant survival stratification when combined with pathologist classification for both the Asian (overall survival log-rank test p-value < 0.005, HR 1.43 (95% CI 1.05–1.66, p-value = 0.03) and European cohorts (overall survival log-rank test p-value < 0.005, HR 1.56 (95% CI 1.16–1.76, p-value < 0.005)).

Conclusion

Our study shows that gastric adenocarcinoma subtyping using pathologist’s Laurén classification as ground truth can be performed using current state of the art DL techniques. Patient survival stratification seems to be better by DL-based histology typing compared with expert pathologist histology typing. DL-based GC histology typing has potential as an aid in subtyping. Further investigations are warranted to fully understand the underlying biological mechanisms for the improved survival stratification despite apparent imperfect classification by the DL algorithm.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology-new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16:703–15.CrossRefPubMedPubMedCentral Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology-new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16:703–15.CrossRefPubMedPubMedCentral
2.
go back to reference Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022;3:1026–38.CrossRefPubMed Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022;3:1026–38.CrossRefPubMed
3.
go back to reference Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Br J Cancer. 2021;124:686–96.CrossRefPubMed Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Br J Cancer. 2021;124:686–96.CrossRefPubMed
4.
go back to reference Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25:1054–6.CrossRefPubMedPubMedCentral Kather JN, Pearson AT, Halama N, Jäger D, Krause J, Loosen SH, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25:1054–6.CrossRefPubMedPubMedCentral
6.
go back to reference Cifci D, Foersch S, Kather JN. Artificial intelligence to identify genetic alterations in conventional histopathology. J Pathol. 2022;257:430–44.CrossRefPubMed Cifci D, Foersch S, Kather JN. Artificial intelligence to identify genetic alterations in conventional histopathology. J Pathol. 2022;257:430–44.CrossRefPubMed
8.
go back to reference Laurén P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed Laurén P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed
9.
go back to reference Jimenez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, et al. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON national cancer registry. Br J Cancer. 2017;117:775–82.CrossRefPubMedPubMedCentral Jimenez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, et al. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON national cancer registry. Br J Cancer. 2017;117:775–82.CrossRefPubMedPubMedCentral
11.
go back to reference Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(476–85):485.e1-11. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(476–85):485.e1-11.
12.
go back to reference Götze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, et al. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer. 2021;21:1158.CrossRefPubMedPubMedCentral Götze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, et al. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO. BMC Cancer. 2021;21:1158.CrossRefPubMedPubMedCentral
13.
go back to reference Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol. 2020;12:1758835920930359.CrossRefPubMedPubMedCentral Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol. 2020;12:1758835920930359.CrossRefPubMedPubMedCentral
15.
go back to reference Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85:50–63.CrossRefPubMed Gullo I, Carneiro F, Oliveira C, Almeida GM. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85:50–63.CrossRefPubMed
16.
go back to reference Gao J-P, Xu W, Liu W-T, Yan M, Zhu Z-G. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J Gastroenterol. 2018;24:2567–81.CrossRefPubMedPubMedCentral Gao J-P, Xu W, Liu W-T, Yan M, Zhu Z-G. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J Gastroenterol. 2018;24:2567–81.CrossRefPubMedPubMedCentral
17.
go back to reference Stelzner S, Emmrich P. The mixed type in Laurén’s classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol. 1997;143:39–48.PubMed Stelzner S, Emmrich P. The mixed type in Laurén’s classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol. 1997;143:39–48.PubMed
18.
go back to reference Pyo JH, Lee H, Min B-H, Lee JH, Choi MG, Lee JH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol. 2017;52:594–601.CrossRefPubMed Pyo JH, Lee H, Min B-H, Lee JH, Choi MG, Lee JH, et al. Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. J Gastroenterol. 2017;52:594–601.CrossRefPubMed
19.
go back to reference Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.CrossRefPubMed Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.CrossRefPubMed
20.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1–21.CrossRef
21.
go back to reference Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Orthod. 2003;21:2070–6. Gill S, Shah A, Le N, Cook EF, Yoshida EM. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Orthod. 2003;21:2070–6.
22.
go back to reference Jin H, Pinheiro PS, Callahan KE, Altekruse SF. Examining the gastric cancer survival gap between Asians and whites in the United States. Gastric Cancer. 2017;20:573–82.CrossRefPubMed Jin H, Pinheiro PS, Callahan KE, Altekruse SF. Examining the gastric cancer survival gap between Asians and whites in the United States. Gastric Cancer. 2017;20:573–82.CrossRefPubMed
23.
go back to reference Ghaffari Laleh N, Truhn D, Veldhuizen GP, Han T, van Treeck M, Buelow RD, et al. Adversarial attacks and adversarial robustness in computational pathology. Nat Commun. 2022;13:1–10.CrossRef Ghaffari Laleh N, Truhn D, Veldhuizen GP, Han T, van Treeck M, Buelow RD, et al. Adversarial attacks and adversarial robustness in computational pathology. Nat Commun. 2022;13:1–10.CrossRef
24.
go back to reference Ulase D, Heckl S, Behrens H-M, Krüger S, Röcken C. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Histopathology. 2020;76:433–46.CrossRefPubMed Ulase D, Heckl S, Behrens H-M, Krüger S, Röcken C. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Histopathology. 2020;76:433–46.CrossRefPubMed
25.
go back to reference Hayashi T, Yoshikawa T, Bonam K, Sue-Ling HM, Taguri M, Morita S, et al. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer. 2013;119:1330–7.CrossRefPubMed Hayashi T, Yoshikawa T, Bonam K, Sue-Ling HM, Taguri M, Morita S, et al. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer. 2013;119:1330–7.CrossRefPubMed
26.
go back to reference Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63.CrossRefPubMed Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63.CrossRefPubMed
27.
go back to reference Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10:28–55.CrossRefPubMed Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10:28–55.CrossRefPubMed
28.
go back to reference Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–91.CrossRefPubMed Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–91.CrossRefPubMed
29.
go back to reference Loeffler, Echle, Heij, Buelow, Krause. The Aachen protocol for deep learning histopathology: a hands-on guide for data preprocessing. Zenodo: Aachen. Loeffler, Echle, Heij, Buelow, Krause. The Aachen protocol for deep learning histopathology: a hands-on guide for data preprocessing. Zenodo: Aachen.
30.
go back to reference Ghaffari Laleh N, Muti HS, Loeffler CML, Echle A, Saldanha OL, Mahmood F, et al. Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Med Image Anal. 2022;79: 102474.CrossRefPubMed Ghaffari Laleh N, Muti HS, Loeffler CML, Echle A, Saldanha OL, Mahmood F, et al. Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Med Image Anal. 2022;79: 102474.CrossRefPubMed
31.
go back to reference Macenko M, Niethammer M, Marron JS, Borland D, Woosley JT, Guan X, et al. A method for normalizing histology slides for quantitative analysis. 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro. 2009; pp. 1107–1110. Macenko M, Niethammer M, Marron JS, Borland D, Woosley JT, Guan X, et al. A method for normalizing histology slides for quantitative analysis. 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro. 2009; pp. 1107–1110.
36.
go back to reference Brockmoeller S, Echle A, Ghaffari Laleh N, Eiholm S, Malmstrøm ML, Plato Kuhlmann T, et al. Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. J Pathol. 2022;256:269–81.CrossRefPubMed Brockmoeller S, Echle A, Ghaffari Laleh N, Eiholm S, Malmstrøm ML, Plato Kuhlmann T, et al. Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. J Pathol. 2022;256:269–81.CrossRefPubMed
37.
go back to reference Kleppe A, Skrede O-J, De Raedt S, Liestøl K, Kerr DJ, Danielsen HE. Designing deep learning studies in cancer diagnostics. Nat Rev Cancer. 2021;21:199–211.CrossRefPubMed Kleppe A, Skrede O-J, De Raedt S, Liestøl K, Kerr DJ, Danielsen HE. Designing deep learning studies in cancer diagnostics. Nat Rev Cancer. 2021;21:199–211.CrossRefPubMed
Metadata
Title
Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study
Authors
Gregory Patrick Veldhuizen
Christoph Röcken
Hans-Michael Behrens
Didem Cifci
Hannah Sophie Muti
Takaki Yoshikawa
Tomio Arai
Takashi Oshima
Patrick Tan
Matthias P. Ebert
Alexander T. Pearson
Julien Calderaro
Heike I. Grabsch
Jakob Nikolas Kather
Publication date
03-06-2023
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 5/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01398-x

Other articles of this Issue 5/2023

Gastric Cancer 5/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine